BofA downgraded Editas Medicine (EDIT) to Underperform from Buy with a price target of $1, down from $13, after the company recently announced plans to out-license their reni-cel program, which the firm sees lowering the impact of upcoming updates from the RUBY SCD trial at ASH and EdiTHAL thalassemia trial expected by year-end 2024. Deprioritizing reni-cel does make sense from a cash burn perspective, but it removes a significant portion of the firm’s valuation with partner interest remaining to be seen. Given the increasingly competitive nature of SCD and thalassemia development, the firm sees the potential value of reni-cel waning as the field looks to in vivo therapies as the next logical step, adds the analyst, who notes that Editas’ in vivo HSC program is still “several years from prime time.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EDIT:
- Biotech Alert: Searches spiking for these stocks today
- Editas upgraded at Evercore ISI on value of reni-cel, CRISPR platform
- Editas Medicine upgraded to Outperform from In Line at Evercore ISI
- Editas Medicine price target lowered to $11 from $17 at Stifel
- Editas Medicine price target lowered to $8 from $12 at Truist
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
